Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-5.31%
$7.31
0% positive prob.
5-Day Prediction
-13.57%
$6.67
0% positive prob.
20-Day Prediction
+7.21%
$8.28
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q4 2025 | SELL | -5.31% | -13.57% | +7.21% | 100.0% | Pending |
| Q3 2025 | SELL | -5.15% | -15.57% | +7.58% | 100.0% | -1.56% |
SEC 8-K filings with transcript text
Mar 5, 2026 · 100% conf.
1D
-5.31%
$7.31
Act: +3.04%
5D
-13.57%
$6.67
20D
+7.21%
$8.28
intensity-202603050001567264FALSE00015672642026-03-052026-03-05
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4110946-1488089 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 (Address of Principal Executive Offices)(Zip Code)
(203) 221-7381 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:Trading Symbol(s):Name of Exchange on Which Registered: Common Stock, $0.0001 par value per shareINTSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. From time to time, Intensity Therapeutics, Inc. (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On March 5, 2026, the Company updated the Financial Highlights Slide through December 31, 2025 (the “Slide”) of its investor presentation, which is available on the Investor Relations section of the Company’s website at https://ir.intensitytherapeutics.com. The Slide is also furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02. All figures in the Slide are unaudited and preliminary and are subject to the completion of financial closing procedures, including management’s reviews. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the year ended December 31, 2025. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description 99.1Financial Highlights Slide, dated March 4, 2026
104Cover Page Interactive Data File (formatted in Inline XBRL).
1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 5, 2026
Intensity Therapeutics, Inc.
By:/s/ Lewis H. Bender Name: Lewis H. Bender Title:Chief Executive Officer
[Signature Page to the Form 8-K] 2
Nov 6, 2025 · 100% conf.
1D
-5.15%
$0.46
Act: -6.30%
5D
-15.57%
$0.41
Act: -1.56%
20D
+7.58%
$0.52
Act: +5.00%
intensity-202511060001567264FALSE00015672642025-11-062025-11-06
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4110946-1488089 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 (Address of Principal Executive Offices)(Zip Code)
(203) 221-7381 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:Trading Symbol(s):Name of Exchange on Which Registered: Common Stock, $0.0001 par value per shareINTSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and nine months ended September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description 99.1Press Release issued November 6, 2025.
104Cover Page Interactive Data File (formatted in Inline XBRL).
Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on May 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on August 7, 2025, and the Company's Quarterly Report on Form 10-Q, filed on November 6, 2025. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates. 1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 6, 2025
Intensity Therapeutics, Inc.
By:/s/ Lewis H. Bender Name: Lewis H. Bender Title:Chief Executive Officer
[Signature Page to the Form 8-K] 2
Aug 7, 2025
intensity-202508070001567264FALSE00015672642025-08-072025-08-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4110946-1488089 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 (Address of Principal Executive Offices)(Zip Code)
(203) 221-7381 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:Trading Symbol(s):Name of Exchange on Which Registered: Common Stock, $0.0001 par value per shareINTSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description 99.1Press Release issued August 7, 2025.
104Cover Page Interactive Data File (formatted in Inline XBRL).
Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on May 13, 2025, and the Company's Quarterly Report on Form 10-Q, filed on August 7, 2025. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates. 1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2025
Intensity Therapeutics, Inc.
By:/s/ Lewis H. Bender Name: Lewis H. Bender Title:Chief Executive Officer
[Signature Page to the Form 8-K] 2
This page provides Intensity Therapeutics Inc. (INTS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on INTS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.